题名

胰臟神經內分泌腫瘤的治療

DOI

10.6666/ClinMed.201905_83(5).0054

作者

潘筱芳；林亮羽

关键词

胰臟神經內分泌腫瘤（pancreatic neuroendocrine tumors, PNETs） ； 第1型多發性內分泌瘤病（multiple endocrine neoplasia type 1, MEN1） ； 體抑素類似物（somatostatin analogues, SSA） ； 單株抗體抑製劑（inhibitors of monoclonal antibodies） ； 肽受體放射性核種治療（peptide receptor radionuclide therapy, PRRT） ； 介入性放射治療（interventional radiology）

期刊名称

臨床醫學月刊

卷期/出版年月

83卷5期（2019 / 05 / 31）

页次

325 - 336

内容语文

繁體中文
中文摘要

胰臟神經內分泌腫瘤（pancreatic neuroendocrine tumors, PNETs）可能以一種非家族性獨立的內分泌疾病或者以複雜遺傳病症的一部分來呈現。這些複雜遺傳病症包括第1型多發性內分泌瘤病（multiple endocrine neoplasia type 1, MEN1）。第1型多發性內分泌瘤病是一種顯性遺傳疾病，其特徵是聯合副甲狀腺腫瘤、腦下垂體前葉腫瘤和PNET一起發生。原發PNET的治療主要是手術切除，但對於無法切除的PNET和腫瘤已轉移者的治療方法包括生物制劑療法（例如：體抑素類似物（somatostatin analogues, SSA）、受體抑製劑（inhibitors of receptors）、單株抗體抑製劑（inhibitors of monoclonal antibodies）、化學療法和放射線療法。這些療法對於沒有合併MEN1的PNET患者是有效的；然而，對於有MEN1的患者中使用相同的PNET治療很少有相關療效的臨床試驗報告。治療有MEN1的PNETs患者很具有挑戰性，因為可能同時有其他的腫瘤，且這些其他的腫瘤也有可能早已轉移。本文主要討論胰臟神經內分泌腫瘤的治療方法。
主题分类 醫藥衛生 > 基礎醫學
醫藥衛生 > 社會醫學
参考文献
  1. Akerstrom, G,Hellman, P.(2007).Surgery on neuroendocrine tumours.Best Pract Clin. Endocrinol Metab,21,87-109.
  2. Anlauf, M,Enosawa, T,Henopp, T(2008).Primary lymph node gastrinoma or occult duodenal microgastrinoma with lymph node metastases in a MEN1 patient: the need for a systematic search for the primary tumor.Am J Surg Pathol,32,1101-1105.
  3. Barbier, CE,Garske-Roman, U,Sandstrom, M(2016).Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases.Eur J Nucl Med Mol Imag,43,1425-1411.
  4. Bendell, JC,Zakari, A,Lang, E(2016).A phase II study of the combination of bevacizumab, pertuzumab, and octreotide lar for patients with advanced neuroendocrine cancers.Cancer Invest,34,213-219.
  5. Broder, LE,Carter, SK(1973).Pancreatic islet cell carcinoma. I. Clinical features of 52 patients.Ann Intern Med,7,101-107.
  6. Caplin, ME,Pavel, M,Cwikla, JB(2014).Lanreotide in metastatic enteropancreatic neuroendocrine tumors.N Engl J Med,371,224-233.
  7. Chan, JA,Blaszkowsky, L,Stuart, K(2013).A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.Cancer,119,3212-3218.
  8. Crippa, S,Partelli, S,Boninsegna, L(2012).Implications of the new histological classification(WHO 2010) for pancreatic neuroendocrine neoplasms.Ann Oncol,23,1928.
  9. Dasari, A,Phan, A,Gupta, S(2015).Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.Endocr Relat Cancer,22,431-441.
  10. Dean, PG,van Heerden, JA,Farley, DR(2000).Are patients with multiple endocrine neoplasia type I prone to premature death?.World J Surg,24,1437-1441.
  11. Dreijerink, KM,Goudet, P,Burgess, JR(2014).Breast-cancer predisposition in multiple endocrine neoplasia type 1.N Engl J Med,371,583-584.
  12. Ehehalt, F,Saeger, HD,Schmidt, CM(2009).Neuroendocrine tumors of the pancreas.Oncologist,14,456-467.
  13. Ekeblad, S,Sundin, A,Janson, ET(2007).Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.Clin. Cancer Res,13,2986-2991.
  14. Faiss, S,Pape, UF,Bohmig, M(2003).Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group.J Clin Oncol,21,2689-2696.
  15. Falconi, M,Eriksson, B,Kaltsas, G(2016).ENETS Consensus Guidelines Update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors.Neuroendocrinology,103,153-171.
  16. Fiore, F,Del Prete, M,Franco, R(2014).Transarterial embolization(TAE) is equally effective and slightly safer than transarterial chemoembolization(TACE) to manage liver metastases in neuroendocrine tumors.Endocr,47,177-182.
  17. Fraenkel, M,Kim, MK,Faggiano, A(2012).Epidemiology of gastroenteropancreatic neuroendocrine tumours.Best Pract. Res. Clin. Gastroenterol,26,691-703.
  18. Frilling, A,Akerstrom, G,Falconi, M(2012).Neuroendocrine tumor disease: an evolving landscape.Endocr Relat Cancer,19,R163-R185.
  19. Frost, M,Lines, KE,Thakker, RV(2018).Current and emerging therapies for PNETs in patients with or without MEN1.Nat Rev Endocrin,14,216-227.
  20. Gamblin, TC,Christians, K,Pappas, SG(2011).Radiofrequency ablation of neuroendocrine hepatic metastasis.Surg Oncol Clin N Am,20,273-279.
  21. Garcia-Carbonero, R,Sorbye, H,Baudin, E(2016).ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas.Neuroendocrinology,103,186-194.
  22. Gaur, SK,Friese, JL,Sadow, CA(2011).Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver.Cardiovasc Intervent Radiol,34,566-572.
  23. Goudet, P,Murat, A,Binquet, C(2010).Risk factors and causes of death in MEN1 disease. A GTE(Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients.World J Surg,34,249-255.
  24. Hammel, P,Hentic, O,Neuzillety, C(2012).New treatment options with cytotoxic agents in neuroendocrine tumours.Target Oncol,7,169-172.
  25. Isacoff, WH,Moss, RA,Pecora, AL(2006).Temozolomide/capecitabine therapy for metastatic neuroendocrine tumors of the pancreas. A retrospective review.J Clin Oncol,24,14021-14023.
  26. Ito, T,Igarashi, H,Uehara, H(2013).Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.Med,92,135-181.
  27. Jensen, RT,Berna, MJ,Bingham, DB(2008).Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.Cancer,113,1807-1843.
  28. Jiao, Y,Shi, C,Edil, BH(2011).DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuro-endocrine tumors.Science,331,1199-1203.
  29. Kouvaraki, MA,Ajani, JA,Hoff, P(2004).Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas.J Clin Oncol,22,4762-4771.
  30. Lemos, MC,Thakker, RV(2008).Multiple endocrine neoplasia type 1(MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene.Hum Mutat,29,22-32.
  31. Marx, S,Spiegel, AM,Skarulis, MC(1998).Multiple endocrine neoplasia type 1: clinical and genetic topics.Ann Intern Med,129,484-494.
  32. Massironi, S,Sciola, V,Peracchi, M(2008).Neuroendocrine tumors of the gastro-entero-pancreatic system.World J Gastroenterol,14,5377-5384.
  33. Moertel, CG,Hanley, JA,Johnson, LA(1980).Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet- cell carcinoma.N Engl J Med,303,1189-1194.
  34. Moertel, CG,Lefkopoulo, M,Lipsitz, S(1992).Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.N Engl J Med,326,519-523.
  35. Newey, PJ,Jeyabalan, J,Walls, GV(2009).Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors.J Clin Endocrinol Metab,94,3640-3646.
  36. Norton, JA(2005).Surgical treatment and prognosis of gastrinoma.Best Pract Res Clin Gastroenterol,19,799-805.
  37. Oberg, K(2009).Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors).Curr Opin Endocrinol Diabetes Obes,16,72-78.
  38. Pavel, M,Baudin,E,Couvelard, A(2012).ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.Neuroendocrinology,95,157-176.
  39. Pavel, ME,Hainsworth, JD,Baudin, E(2011).Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome(RADIANT-2): a randomised, placebo-controlled, phase 3 study.Lancet,378,2005-2012.
  40. Pea, A,Hruban, RH,Wood, LD(2015).Genetics of pancreatic neuroendocrine tumors: implications for the clinic.Expert Rev Gastroenterol Hepatol,9,1407-1419.
  41. Phan, AT,Halperin, DM,Chan, JA(2015).Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.Lancet Oncol,16,695-703.
  42. Pieterman, CR,Schreinemakers, JM,Koppeschaar, HP(2009).Multiple endocrine neoplasia type 1(MEN1): its manifestations and effect of genetic screening on clinical outcome.Clin Endocrinol.,70,575-581.
  43. Ramundo, V,Del Prete, M,Marotta, V(2014).Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours.Clin Endocrinol,80,850-855.
  44. Raymond, E,Dahan, L,Raoul, JL(2011).Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.N Engl J Med,64,501-513.
  45. Rindi, G,Bordi, C(2003).Highlights of the biology of endocrine tumours of the gut and pancreas.Endocr Relat Cancer,10,427-436.
  46. Rossi, S,Viera, FT,Ghittoni, G(2014).Radiofrequency ablation of pancreatic neuroendocrine tumors: a pilot study of feasibility, efficacy, and safety.Pancreas,43,938-945.
  47. Sakurai, A,Katai, M,Yamashita, K(2007).Long-term follow-up of patients with multiple endocrine neoplasia type 1.Endocr J,54,295-302.
  48. Sansovini, M,Severi, S,Ambrosetti, A(2013).Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors.Neuroendocrinology,97,347-354.
  49. Schaaf, L,Pickle, J,Zinner, K(2007).Developing effective screening strategies in multiple endocrine neoplasia type 1(MEN 1) on the basis of clinical and sequencing data of German patients with MEN 1. Exp.Clin Endocrinol Diabetes,115,509-517.
  50. Schmid, HA,Silva, AP(2005).Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats.J Endocrinol Invest,28,28-35.
  51. Scoazec, JY(2013).Angiogenesis in neuroendocrine tumors: therapeutic applications.Neuroendocrinology,97,45-56.
  52. Sorbye, H,Strosberg, J,Baudin, E(2014).Gastroenteropancreatic high-grade neuroendocrine carcinoma.Cancer,120,2814-2823.
  53. Strosberg, JR,Weber, JM,Choi, J(2012).A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors.Ann Oncol,23,2335-2341.
  54. Thakker, R. V.(2014).Multiple endocrine neoplasia type 1(MEN1) and type 4 (MEN4).Mol Cell Endocrinol,386,2-15.
  55. Thakker, RV,Newey, PJ,Walls, GV(2012).Clinical practice guidelines for multiple endocrine neoplasia type 1(MEN1).J Clin Endocrinol Metab,97,2990-3011.
  56. Villard, L,Romer, A,Marincek, N(2012).Cohort study of somatostatin-based radiopeptide therapy with [90Y-DOTA]-TOC versus [90Y-DOTA]-TOC plus [177Lu-DOTA]-TOC in neuroendocrine cancers.J Clin Oncol,30,1100-1106.
  57. Walter, T,Brixi-Benmansour, H,Lombard-Bohas, C(2012).New treatment strategies in advanced neuroendocrine tumours.Dig Liver Dis,44,95-105.
  58. Yao JC,Shah, MH,Ito T(2011).Everolimus for advanced pancreatic neuroendocrine tumors.N Engl J Med,364,514-523.
  59. Yao, JC,Phan, AT,Hess, K(2015).Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors.Pancreas,44,190-197.
  60. Yates, CJ,Newey, PJ,Thakker, RV(2015).Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1.Lancet Diabetes Endocrinol,3,895-905.
被引用次数
  1. 李俊德;林可瀚(2024)。鎦177標記之攝護腺特異性膜抗原放射核種藥物應用於攝護腺癌治療之簡介。臨床醫學月刊。93(3)。144-148。 
print cancel